Pfizer's Lyme Disease Vaccine Misses Phase 3 Endpoint Despite Showing 73%+ Efficacy
By FieldPulse Editorial · March 24, 2026
Tags: Clinical Trials, FDA, Pipeline
The Pfizer-Valneva Lyme disease vaccine showed more than 73% efficacy in a Phase 3 trial but missed its predetermined statistical threshold, leaving the regulatory path uncertain for what would have been the first Lyme vaccine approved in over two decades.
A Phase 3 trial of the Pfizer-Valneva Lyme disease vaccine has produced a result that is at once encouraging and commercially disappointing: the vaccine demonstrated efficacy above 73%, but failed to cross the predetermined statistical confidence interval required to meet the trial's primary endpoint.
Pfizer said it plans to discuss the results and potential regulatory options with the FDA.
The company has not ruled out a path to approval, but the missed primary endpoint introduces meaningful uncertainty into a program that had generated significant interest — Lyme disease affects hundreds of thousands of Americans annually, and there has been no approved Lyme vaccine on the U.S.
market for more than two decades.
The last Lyme vaccine, GlaxoSmithKline's LYMErix, was withdrawn from the market in 2002 amid declining sales and public concern about side effects that were ultimately not confirmed by scientific evidence.
The Pfizer-Valneva program represented the most advanced effort to bring a new option to market since then, and it had attracted attention from public health officials, infectious disease specialists, and patients in endemic regions.
Missing a primary endpoint despite meaningful observed efficacy is a scenario that plays out periodically in late-stage drug and vaccine development.
The outcome leaves the program in a regulatory gray zone: the data are not a clean failure, but they are not the clear success needed for a straightforward approval filing.
How FDA views the totality of the evidence — and whether the agency is willing to work with Pfizer toward a path that accounts for the unmet need — will likely determine what happens next.
For field reps in infectious disease or vaccines, this outcome illustrates the high-stakes nature of late-stage pivotal trials and the consequences when statistical design and observed clinical results diverge.
It also keeps the Lyme prevention market — where there are currently no approved vaccine options — in limbo for pa.
Source: https://www.biospace.com/